Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
Fish and Richardson
Baxter
Farmers Insurance
Johnson and Johnson
Moodys
Medtronic
UBS

Generated: August 17, 2018

DrugPatentWatch Database Preview

Intersect Ent Inc Company Profile

« Back to Dashboard

What is the competitive landscape for INTERSECT ENT INC, and when can generic versions of INTERSECT ENT INC drugs launch?

INTERSECT ENT INC has one approved drug.

There are ten US patents protecting INTERSECT ENT INC drugs.

There are twenty-four patent family members on INTERSECT ENT INC drugs in ten countries and two supplementary protection certificates in two countries.

Summary for Intersect Ent Inc
International Patents:24
US Patents:10
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Intersect Ent Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 7,662,141 ➤ Try a Free Trial ➤ Try a Free Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 7,544,192 ➤ Try a Free Trial ➤ Try a Free Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 8,109,918 ➤ Try a Free Trial ➤ Try a Free Trial
Intersect Ent Inc SINUVA mometasone furoate IMPLANT;IMPLANTATION 209310-001 Dec 8, 2017 RX Yes No 8,025,635 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Intersect Ent Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,951,135 Sinus delivery of sustained release therapeutics ➤ Try a Free Trial
7,662,142 Sinus delivery of sustained release therapeutics ➤ Try a Free Trial
9,782,283 Methods and devices for crimping self-expanding devices ➤ Try a Free Trial
8,337,454 Device and methods for treating paranasal sinus conditions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Intersect Ent Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0002 Belgium ➤ Try a Free Trial PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
C/GB97/064 United Kingdom ➤ Try a Free Trial PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Baxter
McKinsey
US Army
Chubb
QuintilesIMS
Fish and Richardson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.